Loading...
01/09 10:23
Loading...
AbbVie Inc (ABBV) is set to release its FY2025Q1 earnings performance on 04/25 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 12.92B and an earnings per share (EPS) of 2.39 for the FY2025Q1. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings prediction is neutral due to balanced positive and negative factors affecting the company's financial performance.
Fact Data Analysis:
Positive: Rinvoq received EU approval for giant cell arteritis (GCA), expanding its addressable market. BofA noted "modest increases in Skyrizi and Rinvoq sales" for Q1, aligning with consensus.
Negative: Goldman Sachs highlighted that Skyrizi/Rinvoq growth is now "fully appreciated," reducing room for upside surprises.
Rationale: Mixed signals in Fact Data (modest Immunology growth vs. EPS headwinds) favor a neutral outcome. Market expectations are tempered (stock underperformed S&P 500), but EPS guidance cuts limit upside.
AbbVie has raised its revenue and EPS guidance, indicating strong financial performance. Skyrizi and Rinvoq are expected to exceed guidance, and there is optimism in the neuroscience and immunology portfolios. Despite challenges in the aesthetics market and Humira erosion, the company anticipates growth driven by pipeline advancements and strategic acquisitions. The Q&A highlighted strong competitive positioning and market share gains. While some uncertainties remain, the overall sentiment is positive, suggesting a stock price increase in the short term.
AbbVie's earnings call reveals strong financial performance and optimistic guidance, with raised EPS and revenue expectations. The Q&A session highlights confidence in key products like Skyrizi and Rinvoq, despite minor biosimilar impacts. Neuroscience and pipeline growth are promising, while aesthetics face challenges. Management's strategic focus on pipeline development and business expansion supports positive sentiment. Overall, the company's robust outlook and strategic initiatives indicate a likely positive stock price movement over the next two weeks.
AbbVie Inc (ABBV) is scheduled to release its FY2025Q1 earnings report onApr 25, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 12.92B in revenue and an EPS of 2.39 for AbbVie Inc's FY2025Q1.
Intellectia's exclusive AI algorithms forecast a Neutral forAbbVie Inc's FY2025Q1 earnings, with a prediction date of Apr 25, 2025. AbbVie Inc The earnings prediction is neutral due to balanced positive and negative factors affecting the company's financial performance.
Leverage Intellectia's AI forecast to position trades ahead of theApr 25, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!
